Human HLA-DR

Mouse

Human, Monkey (tested or 100% immunogen sequence identity)

IgG3,k Monoclonal

IPO-10

Unconjugated

Protein G purified

Unmodified. Also available Azide-free, BSA-free.

Spleen cells from a patient with hairy cell leukemia were used as the immunogen for the HLA-DR antibody.

Human HLA-DR.

• Immunofluorescence (0.5 - 1 µg/ml)
• Flow Cytometry (0.5 - 1 µg/10E6 cells)

mAb IPO-10 defines the antigen, which appears on B cell progenitors following HLA-DR and preceding CD10, CD19, CD22, CD37 and cym. It is expressed on resting B cells and than reappears and persists in cytoplasm and on cell surface until cytoplasmic Ig appears. It is a useful antibody for diagnostics of neoplasms of B cell origins. It reacts with human B cell lines Daudi, Raji, Namalva, EB-3, RPMI-8226 (50% of cells). The mAb does not label T cell lines, blood granulocytes, thymocytes or bone marrow stromal fibroblasts. No significant changes are detected after PHA or ConA stimulation while LPS and PWM stimulated cultures after 18-48h show decreased number of antigen-positive cells but in final terms of cultivation antigen is expressed again. This mAb labels B cell leukemias and some lymphomas. Hairy cell leukemia strongly reacts and 70% of B cell CLL and some B-NHL were also positive. IPO-10 reacts with AMML cells and in a majority of Hodgkin's disease cases a significant percentage of affected lymph node cells were detected. Optimal dilution of the HLA-DR antibody should be determined by the researcher.

1X PBS, 0.1 mg/ml BSA, 0.05% sodium azide

Store at 2°C to 8°C.

For research use only. Intended for use by laboratory professionals.

This antibody carries the LSBio 100% Guarantee.